Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Journal Articles

The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe

Maria Diez-Campelo, Sophie Park, Tracey Iraca, Mrudula B. Glassberg, Marc DeCongelio, Alison Bulkley, Abisola Olopoenia, Jennifer Lord-Bessen, Grace Skiles, Katie Aguinaga, Neelanzana Paudel, Oliver Will, Dimana Miteva, Christina Hughes, Ahmed Hnoosh, Aylin Yucel

Blood (2024) 144 (Supplement 1): 118.

https://doi.org/10.1182/blood-2024-198393

Published: 2024

Journal Articles

Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial

Valeria Santini, Amer M. Zeidan, Uwe Platzbecker, Rami S. Komrokji, Guillermo Garcia-Manero, Dimana Miteva, Aylin Yucel, Veronika Pozharskaya, Shelonitda Rose, Yinzhi Lai, Ana Carolina Giuseppi, David Valcárcel Ferreiras, Pierre Fenaux, Jake Shortt, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1818.

https://doi.org/10.1182/blood-2024-194239

Published: 2024

Journal Articles

Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial

Guillermo Garcia-Manero, Matteo Giovanni Della Porta, Valeria Santini, Amer M. Zeidan, Rami S. Komrokji, Pierre Fenaux, David Valcárcel, Jake Shortt, Mrudula B. Glassberg, Aylin Yucel, Yinzhi Lai, Dimana Miteva, Shelonitda Rose, Ahmed Hnoosh, Uwe Platzbecker

Blood (2024) 144 (Supplement 1): 1832.

https://doi.org/10.1182/blood-2024-198304

Published: 2024

Journal Articles

Effect of Fedratinib Versus Best Available Therapy on Patient-Reported Outcomes in Patients with Myelofibrosis Who Were Previously Treated with Ruxolitinib: Results from the Phase 3 FREEDOM2 Trial

Claire Harrison, Jennifer Lord-Bessen, Ling Shi, Shien Guo, Aylin Yucel, Dorothy Zissler, Shalon Jones, Samantha Slaff

Blood (2024) 144 (Supplement 1): 6624.

https://doi.org/10.1182/blood-2024-198368

Published: 2024

Journal Articles

Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study

Esther Natalie Oliva, Uwe Platzbecker, Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Pierre Fenaux, Jake Shortt, Rami S. Komrokji, Christopher G. Pelligra, Shien Guo, Aylin Yucel, Mrudula B. Glassberg, Laurie Eliason, Ahmed Hnoosh, Dimana Miteva, Shelo Rose, Sandra Kreitz, Mikkael A. Sekeres, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3216.

https://doi.org/10.1182/blood-2024-198374

Published: 2024

Journal Articles

Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain

Maria Diez-Campelo, Elizabeth Esterberg, Ravi K. Goyal, Mrudula B. Glassberg, Aylin Yucel, Julien Rombi, Keith L. Davis, Maria Jimenez, Dimana Miteva, Ahmed Hnoosh, Ulrich Germing

Blood (2024) 144 (Supplement 1): 5055.

https://doi.org/10.1182/blood-2024-206948

Published: 2024

Journal Articles

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Esther Natalie Oliva, Uwe Platzbecker, Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Pierre Fenaux, Jake Shortt, Rami S. Komrokji, Christopher Pelligra, Shien Guo, Jennifer Lord-Bessen, Hong Xiao, Aylin Yucel, Dimana Miteva, Shelonitda Rose, Sandra Kreitz, Mikkael A. Sekeres, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2023-174660

Published: 2023

Journal Articles

Patient Characteristics, Treatment Patterns, and Health Outcomes in a Real-World Population of Patients with Myelofibrosis Treated with Fedratinib

Francesco Passamonti, Rohan C. Parikh, Siddhi Korgaonkar, Manoj Chevli, Samantha Slaff, Julien Rombi, Basirat Adeyemi, Keith L. Davis, Aylin Yucel

Blood (2023) 142 (Supplement 1): 2425.

https://doi.org/10.1182/blood-2023-173420

Published: 2023

Journal Articles

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Been Treated with Luspatercept

Ralph Boccia, Hong Xiao, Dimana Miteva, Min Che, Tao Gu, Ali McBride, Mrudula B. Glassberg, Aylin Yucel

Blood (2023) 142 (Supplement 1): 7411.

https://doi.org/10.1182/blood-2023-173360

Published: 2023

Journal Articles

Net Clinical and Quality of Life Benefit of Luspatercept in Transfusion-Dependent MDS: A Win Ratio Analysis Using Data from the Phase 3 MEDALIST Study

Esther Natalie Oliva, Christopher Pelligra, Jennifer Lord-Bessen, Shien Guo, Jan Sieluk, Mrudula B. Glassberg, Dimana Miteva, Aylin Yucel

Blood (2023) 142 (Supplement 1): 6467.

https://doi.org/10.1182/blood-2023-173368

Published: 2023

Journal Articles

Clinical Burden of β-Thalassemia: Findings from a Multinational Medical Record Abstraction Study

Maria Domenica Domenica Cappellini, Aylin Yucel, Juliana Meyers, Maria Jimenez, Tram Nham, Mrudula B. Glassberg, Ferras Alashkar

Blood (2022) 140 (Supplement 1): 10877–10878.

https://doi.org/10.1182/blood-2022-156549

Published: 2022

Journal Articles

Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial

Valeria Santini, Pierre Fenaux, Amer M. Zeidan, Rami S. Komrokji, Rena Buckstein, Esther Natalie Oliva, Xianwei Ha, Dimana Miteva, Aylin Yucel, Jose Alberto Nadal, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 4079–4081.

https://doi.org/10.1182/blood-2022-157489

Published: 2022

Journal Articles

Treatment Patterns and Outcomes in Lower-Risk, Non-Del(5q) Myelodysplastic Syndromes: Findings from a Global Real-World Medical Record Review Study

Maria Diez-Campelo, Aylin Yucel, Ravi K. Goyal, Rohan C. Parikh, Elizabeth Esterberg, Maria Jimenez, Martina Sluga-O'Callaghan, Dimana Miteva, Hong Xiao, Ulrich Germing

Blood (2022) 140 (Supplement 1): 13308–13309.

https://doi.org/10.1182/blood-2022-156411

Published: 2022

Journal Articles

Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes: Systematic Literature Review

Ralph V. Boccia, Sohan Deshpande, Caroline von Wilamowitz-Moellendorff, Renuka Raorane, Sven L. Klijn, Hong Xiao, Aylin Yucel

Blood (2022) 140 (Supplement 1): 12355–12356.

https://doi.org/10.1182/blood-2022-156783

Published: 2022

Journal Articles

Real-World Evidence on Treatment Utilization in Lower-Risk Myelodysplastic Syndromes: Findings from a Medical Record Review in the United States

Ulrich Germing, Ravi K. Goyal, Aylin Yucel, Rohan C. Parikh, Maria Jimenez, Martina Sluga-O'Callaghan, Derek Tang, Christina Hughes, Maria Diez-Campelo

Blood (2021) 138 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2021-145576

Published: 2021

Journal Articles

Systematic Literature Review of the Indirect Costs, Humanistic Burden, Patient or Caregiver Preference, and Qualitative Outcomes in Beta-Thalassemia

Yesim Aydinok, Sneha Purushotham, Aylin Yucel, Sohan Deshpande, Barbara Potrata, Myrto Trapali, Mrinalini Dixit, Farrukh Shah

Blood (2021) 138 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2021-145290

Published: 2021

Journal Articles

Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent β-Thalassemia in the BEYOND Trial

Antonis Kattamis, Vip Viprakasit, Maria Domenica Cappellini, Ersi Voskaridou, Antonio Piga, John B. Porter, Thomas D. Coates, Gian Luca Forni, Jeevan K. Shetty, Dimana Miteva, Oriana Esposito, Wen-Ling Kuo, Shien Guo, Christopher Pelligra, Jennifer Lord-Bessen, Aylin Yucel, Ali T. Taher

Blood (2021) 138 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2021-148535

Published: 2021

Journal Articles

Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study

Uwe Platzbecker, Valeria Santini, Rami S. Komrokji, Amer M. Zeidan, Guillermo Garcia-Manero, Rena J. Buckstein, Shelonitda Rose, Shannon Fabre, Dimana Miteva, Jennie Zhang, Aylin Yucel, Christina Hughes, Pierre Fenaux

Blood (2021) 138 (Supplement 1): 1524.

https://doi.org/10.1182/blood-2021-145723

Published: 2021

NARROW

The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe

Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial

Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial

Effect of Fedratinib Versus Best Available Therapy on Patient-Reported Outcomes in Patients with Myelofibrosis Who Were Previously Treated with Ruxolitinib: Results from the Phase 3 FREEDOM2 Trial

Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study

Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Patient Characteristics, Treatment Patterns, and Health Outcomes in a Real-World Population of Patients with Myelofibrosis Treated with Fedratinib

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Been Treated with Luspatercept

Net Clinical and Quality of Life Benefit of Luspatercept in Transfusion-Dependent MDS: A Win Ratio Analysis Using Data from the Phase 3 MEDALIST Study

Clinical Burden of β-Thalassemia: Findings from a Multinational Medical Record Abstraction Study

Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial

Treatment Patterns and Outcomes in Lower-Risk, Non-Del(5q) Myelodysplastic Syndromes: Findings from a Global Real-World Medical Record Review Study

Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes: Systematic Literature Review

Real-World Evidence on Treatment Utilization in Lower-Risk Myelodysplastic Syndromes: Findings from a Medical Record Review in the United States

Systematic Literature Review of the Indirect Costs, Humanistic Burden, Patient or Caregiver Preference, and Qualitative Outcomes in Beta-Thalassemia

Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent β-Thalassemia in the BEYOND Trial

Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only